IGF2BP1 and Schnyder corneal dystrophy: Transplantation studies performed using healthy mice and models of β-thalassemia or SCD will be required to rigorously test the utility and safety of IGF2BP1 as a new therapeutic avenue for patients with severe β-hemoglobin disorders.